AstraZeneca’s Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination, has been approved in the European Union (EU) for the treatment of adults and adolescents (aged 12 years and older weighing at least 40 kg) with COVID‑19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID‑19.
Evusheld long-acting antibody combination approved in the EU for the treatment of COVID-19
September 29, 2022
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022